After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
ESMO: AstraZeneca faces challenge with FDA as Imfinzi, Lynparza miss survival goal in ovarian cancer
More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival ...
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback